MELD 3.0: Exploring and expanding its utility beyond transplantation

Area of Science:

• Hepatology
• Transplantation Medicine
• Critical Care Medicine

Background:

• The Model for End-Stage Liver Disease (MELD) score is crucial for liver transplant prioritization.
• MELD 3.0, incorporating serum albumin and sex-adjusted variables, enhances predictive accuracy.
• This review explores MELD 3.0's utility beyond transplant selection.

Purpose of the Study:

• To examine the clinical applications of MELD 3.0 as a prognostic tool in diverse hepatic and systemic conditions.
• To evaluate MELD 3.0's performance across various clinical scenarios, including transplantation, liver disease complications, and oncology.

Main Methods:

• Review of existing data and studies evaluating MELD 3.0 in different patient populations.
• Comparative analysis of MELD 3.0 against other prognostic models and MELD variants.
• Assessment of MELD 3.0's predictive power for mortality, resource utilization, and treatment response.

Main Results:

• MELD 3.0 shows superior prediction for mortality and ICU needs in heart transplantation.
• It maintains discriminatory ability in acute variceal hemorrhage but requires calibration.
• MELD 3.0 demonstrates moderate predictive value in hepatocellular carcinoma with renal insufficiency, though outperformed by AB-based models.
• It effectively stratifies risk in transjugular intrahepatic portosystemic shunt procedures.
• MELD 3.0 surpasses older models for alcohol-associated hepatitis mortality and RRT prediction.
• In oncology, it aids risk assessment in hepatic visceral crisis.
• Performance is less robust in hepatic hydrothorax and comparable to other MELD variants in spontaneous bacterial peritonitis.

Conclusions:

• MELD 3.0 is a relevant, generalizable risk stratification tool for acute and chronic liver conditions.
• Its incorporation into routine care may improve prognostic precision and guide therapeutic decisions beyond transplantation.
• Further prospective validation is recommended.